TABLE 1.

Study enrollment, withdrawal, and completion rates^a

Subject characteristic	No. of subjects
	Regimen A	Regimen B	Total
Subjects who were randomized	17	17	34
Subject withdrawal for acute illness before treatment with a single drug was initiated	1	1	2
Subjects evaluable for single-drug tolerance	16	16	32
Subject withdrawal of consent before two drug combination was initiated	1	1	2
Subject noncompliance before two-drug combination was initiated	1	0	1
Subjects evaluable for combination drug tolerance	14	15	29
Subject withdrawal for adverse event after two-drug combination was initiated	1	1	2
Subject noncompliance during two-drug combination	1	0	1
Subjects completing the study	12	14	26
Subjects for whom no pharmacokinetic data were available because of technical problems	1	0	1
Subjects for whom data were evaluable for pharmacokinetic analysis	11	14	25

^aRegimen A, clarithromycin on days 1 to 14 and both study drugs on days 15 to 42; regimen B, rifabutin on days 1 to 14 and both study drugs on days 15 to 42.